Research map: Evaluating the use of GLP-1 receptor agonists in Wolfram syndrome patients

Back to the article

Papers in this map

  1. Once-Weekly Semaglutide in Adults with Overweight or Obesity · John P.H. Wilding · 2021 · 5054 citations · Cited by this paper
  2. Subclinical primary aldosteronism: toward a conceptual framework linking primary aldosteronism and low-renin hypertension · 2026 · Related
  3. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1 · Daniel J. Drucker · 2018 · 2131 citations · Cited by this paper
  4. Physician and hospital determinants of levothyroxine treatment adequacy in low-risk papillary thyroid carcinoma · 2026 · Related
  5. A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome) · Hiroshi Inoue · 1998 · 764 citations · Cited by this paper
  6. The effects of SARS-CoV-2 on bone homeostasis · 2026 · Related
  7. Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome · Timothy Geoffrey Barrett · 1995 · 640 citations · Cited by this paper
  8. Restless legs syndrome or diabetic peripheral neuropathy: diagnostic dilemmas and clinical insights from a case report · 2026 · Related
  9. Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cells · Sonya G. Fonseca · 2010 · 416 citations · Cited by this paper
  10. Association between metabolic syndrome and mortality among breast cancer survivors: a prospective cohort study · 2026 · Related
  11. WFS1 Is a Novel Component of the Unfolded Protein Response and Maintains Homeostasis of the Endoplasmic Reticulum in Pancreatic β-Cells · Sonya G. Fonseca · 2005 · 370 citations · Cited by this paper
  12. Association of accelerometer-measured physical activity and the risk of incident cardiovascular diseases within the AHA cardiovascular-kidney-metabolic syndrome 0–4 framework: a prospective cohort of the UK Biobank · 2026 · Related
  13. Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity · Patricia J. Rodriguez · 2025 · 341 citations · Cited by this paper
  14. Genotype-based severity scoring system in Wolfram Syndrome: correlation with onset of cardinal symptoms and WFS1 gene variant types · 2026 · Related
  15. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus · Juan José Gorgojo Martínez · 2022 · 340 citations · Cited by this paper
  16. Association of gravidity, parity, and abortion history with nodal metastasis in women with papillary thyroid carcinoma: a retrospective cohort study · 2026 · Related
  17. Wolfram Syndrome: Diagnosis, Management, and Treatment · Fumihiko Urano · 2016 · 311 citations · Cited by this paper
  18. Association between primary aldosteronism and type 2 diabetes and identification of potential molecular mechanisms · 2026 · Related
  19. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment · Katherine O. Kopp · 2022 · 290 citations · Cited by this paper
  20. Optic Atrophy in Wolfram Syndrome Type 1: A Retrospective Analysis of Visual Outcomes and Biomarker Correlates · 2026 · Related
  21. GLP-1-based therapies for diabetes, obesity and beyond · Daniel J. Drucker · 2025 · 224 citations · Cited by this paper
  22. Morbidity and Mortality in the Wolfram Syndrome · Brendan Kinsley · 1995 · 182 citations · Cited by this paper
  23. β-Cell Dysfunction Due to Increased ER Stress in a Stem Cell Model of Wolfram Syndrome · Linshan Shang · 2013 · 180 citations · Cited by this paper
  24. Retinal Nerve Fiber Layer Thickness Reproducibility Using Seven Different OCT Instruments · Luisa Pierro · 2012 · 160 citations · Cited by this paper
  25. A calcium-dependent protease as a potential therapeutic target for Wolfram syndrome · Simin Lu · 2014 · 156 citations · Cited by this paper
  26. Retinal nerve fibre layer thickness floor and corresponding functional loss in glaucoma · Jean-Claude Mwanza · 2014 · 142 citations · Cited by this paper
  27. The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions · Areesha Moiz · 2025 · 139 citations · Cited by this paper
  28. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes—2026 · Mandeep Singh Bajaj · 2025 · 116 citations · Cited by this paper
  29. Early Brain Vulnerability in Wolfram Syndrome · Tamara G. Hershey · 2012 · 115 citations · Cited by this paper
  30. GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits · Michael Albrecht Nauck · 2026 · 96 citations · Cited by this paper
  31. The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases · Dihe Cheng · 2022 · 83 citations · Cited by this paper
  32. Ophthalmologic correlates of disease severity in children and adolescents with Wolfram syndrome · James Hoekel · 2014 · 68 citations · Cited by this paper
  33. Wfs1- deficient rats develop primary symptoms of Wolfram syndrome: insulin-dependent diabetes, optic nerve atrophy and medullary degeneration · Mario Plaas · 2017 · 67 citations · Cited by this paper
  34. Current Landscape of Treatments for Wolfram Syndrome · Damien Abreu · 2019 · 59 citations · Cited by this paper
  35. Activation of GLP-1 receptor signalling alleviates cellular stresses and improves beta cell function in a mouse model of Wolfram syndrome · Manabu Kondo · 2018 · 58 citations · Cited by this paper
  36. GLP-1 receptor agonist liraglutide has a neuroprotective effect on an aged rat model of Wolfram syndrome · Kadri Seppa · 2019 · 57 citations · Cited by this paper
  37. GLP-1 programs the neurovascular landscape · Bandy Chen · 2024 · 56 citations · Cited by this paper
  38. Discovery of GLP-1–Based Drugs for the Treatment of Obesity · Daniel J. Drucker · 2024 · 49 citations · Cited by this paper
  39. The expanding landscape of GLP-1 medicines · Daniel J. Drucker · 2026 · 49 citations · Cited by this paper

Source: OpenAlex (CC0)